The Conversation (0)
Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results
Mar. 09, 2018 08:45AM PST
Medical Device InvestingChembio Diagnostics (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: Achieved total revenue of $24.0 million of which net product sales were $19.3 million for the full year 2017, increases of 34% …
Chembio Diagnostics (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017.
As quoted in the press release:
- Achieved total revenue of $24.0 million of which net product sales were $19.3 million for the full year 2017, increases of 34% and 41% respectively, over prior year
- Received $8.5 million 2018 purchase commitment from Bio-Manguinhos in Brazil for DPP® HIV Assays and DPP® Leishmania Assays
- Won three-year, $15.8 million total contract value tender from the Ethiopian Pharmaceuticals Fund and Supply Agency to deliver HIV STAT-PAK® Assays between 2018-2020
- Received conditional award of $1.5 million to $4.9 million in 2018-2019 from UNICEF for DPP® Zika Systems
